DK1503764T3 - 5-HT4-receptor-antagonister til behandling af hjertesvigt - Google Patents

5-HT4-receptor-antagonister til behandling af hjertesvigt

Info

Publication number
DK1503764T3
DK1503764T3 DK03725415.8T DK03725415T DK1503764T3 DK 1503764 T3 DK1503764 T3 DK 1503764T3 DK 03725415 T DK03725415 T DK 03725415T DK 1503764 T3 DK1503764 T3 DK 1503764T3
Authority
DK
Denmark
Prior art keywords
heart failure
receptor antagonists
treatment
heart
treating
Prior art date
Application number
DK03725415.8T
Other languages
English (en)
Inventor
Finn Olav Levy
Original Assignee
Serodus As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serodus As filed Critical Serodus As
Application granted granted Critical
Publication of DK1503764T3 publication Critical patent/DK1503764T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatment Of Sludge (AREA)
  • Electrotherapy Devices (AREA)
DK03725415.8T 2002-05-16 2003-05-16 5-HT4-receptor-antagonister til behandling af hjertesvigt DK1503764T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0211230.8A GB0211230D0 (en) 2002-05-16 2002-05-16 Treatment of heart failure
PCT/GB2003/002134 WO2003097065A1 (en) 2002-05-16 2003-05-16 5-ht4 receptor antagonists for the treatment of heart failure

Publications (1)

Publication Number Publication Date
DK1503764T3 true DK1503764T3 (da) 2010-05-10

Family

ID=9936797

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03725415.8T DK1503764T3 (da) 2002-05-16 2003-05-16 5-HT4-receptor-antagonister til behandling af hjertesvigt

Country Status (10)

Country Link
US (2) US20060094715A1 (da)
EP (1) EP1503764B1 (da)
AT (1) ATE454153T1 (da)
AU (2) AU2003227949B2 (da)
CA (1) CA2485600C (da)
DE (1) DE60330857D1 (da)
DK (1) DK1503764T3 (da)
ES (1) ES2339234T3 (da)
GB (1) GB0211230D0 (da)
WO (1) WO2003097065A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2963013A4 (en) 2013-02-27 2016-09-14 Shionogi & Co INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
US20170058349A1 (en) * 2014-03-04 2017-03-02 The Children's Hospital Of Philadelphia Methods for managing care of patients predisposed to progressive mitral valve diseases
US20170296506A1 (en) * 2016-04-13 2017-10-19 Board Of Regents Of The University Of Nebraska Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
KR102752382B1 (ko) * 2019-09-20 2025-01-09 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 안지오텐신 ii 수용체 길항제 대사물질 및 nep 억제제의 복합체의 심부전 치료에서의 용도

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3061860D1 (en) 1979-04-24 1983-03-17 Marcel Jozefonvicz Process for the determination of proteases and antiproteases
US4888353A (en) 1986-02-28 1989-12-19 Erbamont, Inc. Carboxamides useful as antiemetic or antipsychotic agents
DE201165T1 (de) 1985-03-14 1989-04-20 Beecham Group P.L.C., Brentford Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
ZA886585B (en) 1987-09-08 1990-05-30 Lilly Co Eli Specific 5-ht,antagonists
CA1317940C (en) 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
ZA889493B (en) 1987-12-24 1989-09-27 Duphar Int Res Method of preparing optically active cyanohydrin derivatives and their conversion products,and optically active compounds to be obtained in this manner
US4859683A (en) * 1988-02-04 1989-08-22 Rorer Pharmaceutical Corporation Certain benzoxepins and their pharmaceutical compositions and methods
JP2643274B2 (ja) 1988-04-08 1997-08-20 三菱化学株式会社 イミダゾ〔１，２−ａ〕ピリジン誘導体
EP0387431A1 (en) 1989-03-14 1990-09-19 Beecham Group Plc Imidazole derivatives, process for their preparation and their pharmaceutical use
IE902465A1 (en) 1989-07-07 1991-02-13 Schering Corp Pharmaceutically active compounds
GB9009389D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
GB9103862D0 (en) 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5137893A (en) * 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5219850A (en) * 1991-03-07 1993-06-15 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5196547A (en) * 1991-03-07 1993-03-23 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5492919A (en) 1991-08-03 1996-02-20 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
CA2116024A1 (en) 1991-08-20 1993-03-04 Francis David King 5-ht4 receptor antagonists
CA2118812C (en) 1991-09-12 2006-01-17 Francis David King 5-ht4 receptor antagonists
US5552398A (en) 1991-09-12 1996-09-03 Smithkline Beecham P.L.C. Azabicyclic compounds as 5-HT4 receptor antagonists
GB9121835D0 (en) 1991-10-15 1991-11-27 Smithkline Beecham Plc Pharmaceuticals
US20020128172A1 (en) * 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
RU2104279C1 (ru) 1992-03-12 1998-02-10 Смитклайн Бичам Плс Конденсированное индольное производное или его фармацевтически приемлемая соль, фармацевтическая композиция, проявляющая активность антагониста 5-нт*004-рецептора
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
GB9219163D0 (en) 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
MX9305947A (es) 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
AU5150393A (en) 1992-10-13 1994-05-09 Smithkline Beecham Plc Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists
MX9306311A (es) 1992-10-13 1994-04-29 Smithkline Beecham Plc Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
GB9221468D0 (en) 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals
US5726187A (en) * 1992-10-16 1998-03-10 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists
NZ257545A (en) 1992-11-05 1997-01-29 Smithkline Beecham Plc Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
GB9301660D0 (en) 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
US6127379A (en) * 1993-02-01 2000-10-03 Smithkline Beecham P.L.C. Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
TW282460B (da) 1993-12-28 1996-08-01 Yamanouchi Pharma Co Ltd
KR970702247A (ko) 1994-03-30 1997-05-13 고야 마사시 벤조산 화합물 및 이들의 약제로서의 용도(benzoic acid compound and use thereof as medicine)
JPH07302236A (ja) * 1994-05-06 1995-11-14 Hitachi Ltd 情報処理システムおよびその方法並びに情報処理システムにおけるサービス提供方法
WO1995032965A1 (en) 1994-06-01 1995-12-07 Yamanouchi Pharmaceutical Co. Ltd. Oxadiazole derivative and medicinal composition thereof
WO1996005166A1 (en) 1994-08-11 1996-02-22 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
DE19581851T1 (de) * 1994-11-21 1998-02-12 Asahi Chemical Ind Härtbares Harz und dieses enthaltende Harzzusammensetzung
ES2103675B1 (es) 1995-01-10 1998-07-01 Almirall Lab Nuevas piperidinas sustituidas.
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
JPH0967347A (ja) 1995-08-30 1997-03-11 Dainippon Pharmaceut Co Ltd 環状アミン誘導体及びそれを含有する医薬組成物
AU707325B2 (en) 1995-11-09 1999-07-08 Sanofi-Aventis 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-HT4 or H3 receptor ligands
JP2000504014A (ja) 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
ES2208870T3 (es) * 1996-02-15 2004-06-16 Janssen Pharmaceutica N.V. Uso de antagonistas del receptor 5ht4 para resolver los efectos gastrointestinales de los inhibidores de la reabsorcion de serotonina.
JP2001519766A (ja) 1996-04-03 2001-10-23 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼの阻害剤
JP3911297B2 (ja) 1996-08-16 2007-05-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｎ―［（１―ｎブチル―４―ピペリジル）メチル］―３，４―ジヒドロ―２Ｈ―［１，３］オキサジノ［３，２―ａ］インドール―１０―カルボキシアミドおよび塩ならびに製造における中間体
FR2752736B1 (fr) 1996-08-30 1998-10-23 Chu Rouen Utilisation d'antagonistes 5-ht4 dans la regulation de la secretion de corticosteroides
GB9618967D0 (en) 1996-09-11 1996-10-23 Smithkline Beecham Plc Pharmaceuticals
JPH10203987A (ja) 1997-01-28 1998-08-04 Dainippon Pharmaceut Co Ltd （ｒ）−１−エチル−４−メチルヘキサヒドロ−１ｈ−１，４−ジアゼピン誘導体を有効成分とするモルヒネ様薬剤誘発嘔吐抑制剤
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
NZ525108A (en) 1998-03-31 2005-02-25 Acadia Pharm Inc Compounds with activity on muscarinic receptors
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
GB9815483D0 (en) 1998-07-16 1998-09-16 Smithkline Beecham Plc Pharmaceuticals
GB9815481D0 (en) 1998-07-16 1998-09-16 Smithkline Beecham Plc Pharmaceuticals
US20020091271A1 (en) * 1998-07-16 2002-07-11 Smithkline Beecham Plc Process for the preparation of an indole derivative
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
AU5406399A (en) * 1999-08-27 2001-03-26 Qingdao Synergy Technology Appliance Co., Ltd. The method for manufacturing vacuum glazing and its application mechanical system
IL154279A0 (en) * 2000-08-07 2003-09-17 Glaxosmithkline Lab Sas Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
AU7655801A (en) 2000-08-08 2002-02-18 Smithkline Beecham Plc Pharmaceutical composition comprising condensed indole compound
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
ATE307812T1 (de) * 2001-10-22 2005-11-15 Pfizer Imidazopyridinverbindungen als 5-ht4- rezeptormodulatoren
US6624162B2 (en) * 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
JP2005523276A (ja) 2002-02-14 2005-08-04 グラクソ　グループ　リミテッド Ｎ−［（１−ｎ−ブチル−４−ピペリジニル）メチル］−３，４−ジヒドロ−２ｈ−［１，３］オキサジノ［３，２−ａ］インドール−１０−カルボキシアミド（ｓｂ２０７２６６）またはその塩および乾燥造粒操作を含む方法
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
EP1629280A2 (en) 2003-05-21 2006-03-01 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
KR100738784B1 (ko) 2003-09-03 2007-07-12 화이자 인코포레이티드 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론
JP4740152B2 (ja) 2003-12-23 2011-08-03 セロドス アクスイェ セルスカブ 末梢性５−ｈｔ受容体の修飾因子
DK2194053T3 (da) 2004-01-07 2013-07-01 Armetheon Inc Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet.
US7843010B2 (en) * 2004-09-30 2010-11-30 Sharp Kabushiki Kaisha Crystalline semiconductor film and method for manufacturing the same
EP1902044A1 (en) 2005-07-07 2008-03-26 Bio Medisinsk Innovasjon AS 5-htx modulators
US7906532B2 (en) 2005-07-22 2011-03-15 Pfizer Inc. Indazole derivatives
US20080085915A1 (en) 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB

Also Published As

Publication number Publication date
ATE454153T1 (de) 2010-01-15
WO2003097065A1 (en) 2003-11-27
ES2339234T3 (es) 2010-05-18
AU2003227949A1 (en) 2003-12-02
GB0211230D0 (en) 2002-06-26
AU2009200050A1 (en) 2009-02-05
US8829028B2 (en) 2014-09-09
DE60330857D1 (de) 2010-02-25
CA2485600C (en) 2010-04-20
AU2003227949B2 (en) 2008-12-11
CA2485600A1 (en) 2003-11-27
HK1072012A1 (en) 2005-08-12
AU2009200050B2 (en) 2010-11-11
US20060094715A1 (en) 2006-05-04
US20090169545A1 (en) 2009-07-02
EP1503764B1 (en) 2010-01-06
EP1503764A1 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
WO2005107726A3 (en) Method for the treatment of back pain
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
TW200633980A (en) Pyridones useful as inhibitors of kinases
TNSN07376A1 (en) Npy antagonists, preparation and use
TW200510416A (en) P38 inhibitors and methods of use thereof
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
BRPI0415709A (pt) esquemas terapêuticos para antagonistas de baff
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
WO2008018827A8 (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same